Neuron-specific enolase (NSE) can be of value in the diagnosis of small cell lung cancer, neuroendocrine tumors, all stages of neuroblastoma, melanoma, seminoma, renal cell carcinoma, Merkel cell tumor, carcinoid tumors, dysgerminomas and immature teratomas, malignant pheochromocytoma, Guillain-Barré syndrome, and Creutzfeldt-Jakob disease.[3] In addition, NSE might be utilized as a prognostic and therapeutic biomarker for neuroinflammation, neurodegeneration, and neuroprotection in spinal cord injury as well as neurodegenerative diseases.[4]. Here, ENO2 is linked to Guillain-Barre syndrome.